Avista Therapeutics Welcomes New Leadership
Avista Therapeutics, a pioneering biotechnology company focused on gene therapies for rare ophthalmic diseases, has announced a significant leadership change by appointing Steven Altschuler, MD, as the Chairman of the Board of Directors. With over two decades of experience in healthcare and biotechnology, Dr. Altschuler is well-positioned to guide Avista in its mission to advance innovative treatments.
Steven Altschuler's Rich Experience
Dr. Altschuler is known for his transformative role in the healthcare sector, having held influential positions across various prestigious organizations. Currently serving as Managing Director of Healthcare Ventures at Ziff Capital Partners, he spearheads initiatives to develop companies with groundbreaking technologies. His prior experience includes co-founding Spark Therapeutics, where he played a crucial role in the launch of LUXTURNA, the first FDA-approved gene therapy for retinal diseases.
A Vision for Gene Therapy
During his tenure at Avista, Dr. Altschuler aims to leverage his extensive background in gene therapy to expand accessible solutions for those affected by retinal diseases. He expressed enthusiasm for the company's innovative scAAVengr platform, which significantly improves delivery vectors, enhancing the efficacy of gene therapies while minimizing invasive procedures.
The Future of Avista Therapeutics
The leadership of Avista Therapeutics under Dr. Altschuler promises to steer the company toward significant breakthroughs in gene therapy. The dedicated team at Avista is committed to translating advanced preclinical research into effective clinical applications, and Dr. Altschuler's experience will undoubtedly bolster these efforts.
Commitment to Innovation
Avista Therapeutics focuses on developing gene therapies that address serious retinal conditions, emphasizing the importance of improving patients' quality of life. Their mission hinges on utilizing advanced tools and expertise to ensure the rapid introduction of new therapies into the clinical environment.
About Avista Therapeutics
Avista Therapeutics is dedicated to advancing the field of gene therapy through cutting-edge research and applications. Their unique scAAVengr platform is designed to create specialized AAV vectors for targeted treatments with minimal invasiveness. This innovative approach allows for precise targeting of specific cell types, significantly improving the potential for clinical success.
Frequently Asked Questions
Who is the new Chairman of Avista Therapeutics?
Steven Altschuler, MD, has been appointed as the new Chairman of the Board of Directors at Avista Therapeutics.
What experience does Steven Altschuler bring?
Dr. Altschuler brings over two decades of experience in leading and developing biotechnology companies, with a strong focus on gene therapies for retinal diseases.
What is the focus of Avista Therapeutics?
Avista Therapeutics is focused on developing innovative gene therapies specifically for rare ophthalmic conditions that impact quality of life.
What is the scAAVengr platform?
The scAAVengr platform is an advanced tool used by Avista Therapeutics to enhance gene therapy delivery vectors and broaden accessibility to treatments.
How does Avista aim to improve gene therapy delivery?
Avista aims to improve gene therapy delivery by leveraging computational techniques to create tailored AAV vectors for effective and minimally invasive treatment options.
